Sensei Biotherapeutics Inc
F:407

Watchlist Manager
Sensei Biotherapeutics Inc Logo
Sensei Biotherapeutics Inc
F:407
Watchlist
Price: 5.2 EUR Market Closed
Market Cap: 138.2m EUR

Sensei Biotherapeutics Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sensei Biotherapeutics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Sensei Biotherapeutics Inc
NASDAQ:SNSE
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$59.6B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$29.1B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Revenue
$36B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$11.7B
CAGR 3-Years
10%
CAGR 5-Years
14%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$14.2B
CAGR 3-Years
1%
CAGR 5-Years
12%
CAGR 10-Years
14%
No Stocks Found

Sensei Biotherapeutics Inc
Glance View

Market Cap
138.2m EUR
Industry
Biotechnology

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 56 full-time employees. The company went IPO on 2021-02-04. The firm is engaged in the discovery and development of therapies with focus on treatments for cancer. Its ImmunoPhage platform is a self-adjuvanted and differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. The firm is engineering its ImmunoPhage product candidates to directly target antigen presenting cells (APCs) and modulate the tumor microenvironment (TME) through the targeted use of nanobodies which enhances therapeutic activity. SNS-301 is an ImmunoPhage product candidate that the Company is developing as a treatment for locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN). The company also develops ImmunoPhage candidate, SNS-401, for the treatment of Merkel cell carcinoma (MCC). The firm is also engaged in developing a monoclonal antibody (mAb) therapy.

Intrinsic Value
15.64 EUR
Undervaluation 67%
Intrinsic Value
Price

See Also

What is Sensei Biotherapeutics Inc's Revenue?
Revenue
0 USD

Based on the financial report for Dec 31, 2024, Sensei Biotherapeutics Inc's Revenue amounts to 0 USD.

Back to Top